|Articles|January 18, 2002
CDER News 12/31/01 through 1/2/02
Author(s)BioPharm International Editors
Original manufacturing supplements, original efficacy supplements, original and resubmitted NDAs, and new and generic drug approvals.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
3
Generative AI and Adaptive Trials Shape Future Biotech Development
4
Novartis Calls for Global Governments to Address Global Trade Policy
5